[14]Gelbert Lawrence M et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.[J]. Investigational new drugs, 2014, 32(5) : 825-37. [15]Raub TJ, Wishart GN, Kulanthaivel P,...
CDK4/6抑制剂的应用不仅局限于HR+/HER2- 乳腺癌患者,在HR+/HER2+患者的临床研究,如Ⅱ期monarcHER研究,比较了阿贝西利、氟维司群、曲妥珠单抗三联与标准化疗联合曲妥珠单抗在HR+/HER2+晚期乳腺癌患者中的疗效。在转移后接受过≥2次抗HER-2治疗、恩美曲妥珠单抗...
[8]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015;26(8):797-806. [9]Schoninger SF and Blain SW. The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer[J]....
CDK4/6 inhibitor acts on cell cycle.It can be used alone or in combination to treat lung cancer,liver cancer,pancreatic cancer and other cancers by restoring normal cell cycle,triggering anti-tumor immunity and changing the microenvironment of tumors.It has a certain therapeutic effect,and has ...
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole ...
Mol Cancer Ther. 2014 Oct;13(10):2253-63. [3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37....
The cyclin-dependent kinases 4 and 6 inhibitors are the mainstay of treatment for patients with hormone receptor-positive and HER2-negative breast cancer. The ability of these drugs to improve the outcome of patients both in the metastatic and the early
To learn more about how these drugs are used, Medscape reached out to experts to discuss practical tips about agent selection and patient monitoring. Impact on Therapy Five years ago, the first CDK4/6 inhibitorpalbociclibwas approved for use in MBC in combination withletrozolefor treating ER-pos...
[3]Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis.2022 ESMO abstract 169P. [4]Dukelow T, Kishan D, Khasraw M, et al. CDK4/6 inhibitors in breast cancer[J]. Anti-cancer drugs. 2015...
The increased and earlier use of CDK4/6 inhibitors has resulted in a better understanding of the mechanisms of acquired resistance; potential treatment combinations that might overcome these mechanisms are being explored. Treatment selection after disease progression on a CDK4/6 inhibitor remains an ar...